Nektar registers Phase 3 atopic dermatitis trial for rezpegaldesleukin
Nektar Therapeutics is recruiting patients for a Phase 3 study testing rezpegaldesleukin against placebo in moderate-to-severe atopic dermatitis.
Nektar Therapeutics has a newly listed Phase 3 trial recruiting participants for its interleukin-based candidate rezpegaldesleukin.
- This Phase 3, randomized, double-blind, placebo-controlled study is evaluating rezpegaldesleukin monotherapy in patients 12 years of age or older with moderate to severe atopic dermatitis1, under the acronym ZENITH AD-1. The study is listed as recruiting, with an estimated enrollment of 510 participants1. The primary outcome for the US population is the number of participants achieving an Investigator's Global Assessment (IGA) score of 0 or 1 with at least a 2-point reduction from baseline at Week 24, where the IGA scale runs from 0 to 4 with higher scores indicating more severe disease.1 The trial's actual start date is listed as June 29, 2026, with an estimated primary completion in May 2028.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.